The sky high cost of drug development means that late stage drug attrition is especially devastating. Thus, the ability to assess potential drug safety issues early— using in vitro data— would be very beneficial. The current paradigm for cardiac safety pharmacology is rooted in the preclinical ICH S7B and clinical ICH E14 guidelines. There have […]Read More
Author: Sebastian Polak
Dr. Sebastian Polak is a Senior Principal Scientist at Simcyp (part of Certara), where he is a member of the modeling and simulation group. He leads the development of cardiac safety modeling and simulation systems based on the biophysical models of human cardiac myocytes operating at the population level (CSS – Cardiac Safety Simulator). Dr. Polak is also a tenured Associate Professor in Biopharmaceutics at the Faculty of Pharmacy at Jagiellonian University in Cracow, Poland. Dr. Polak serves as a reviewer for multiple professional scientific journals and scientific book publishers. He has published over 40 peer-reviewed articles. He earned a DSc Degree in Biopharmacy from the Faculty of Pharmacy at Jagiellonian University Medical College in 2013. He earned a PhD from the Department of Toxicology, Unit of Pharmacoepidemiology and Pharmacoeconomics at Jagiellonian University Medical College in 2006. Dr. Polak earned a Master’s Degree in Pharmacy in 2000 from the Faculty of Pharmacy at Jagiellonian University Medical College.